Research ArticleCancer
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
- Bradon R. McDonald1,
- Tania Contente-Cuomo1,
- Stephen-John Sammut2,
- Ahuva Odenheimer-Bergman1,
- Brenda Ernst3,
- Nieves Perdigones1,
- Suet-Feung Chin2,
- Maria Farooq1,
- Rosa Mejia4,
- Patricia A. Cronin3,
- Karen S. Anderson3,5,
- Heidi E. Kosiorek3,
- Donald W. Northfelt3,
- Ann E. McCullough3,
- Bhavika K. Patel3,
- Jeffrey N. Weitzel4,
- Thomas P. Slavin4,
- Carlos Caldas2,
- Barbara A. Pockaj3,* and
- Muhammed Murtaza1,3,*
- 1Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
- 2Department of Oncology and Cancer Research UK Cambridge Institute and Cancer Centre, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
- 3Mayo Clinic, Scottsdale, AZ 85259, USA.
- 4City of Hope, Duarte, CA 91010, USA.
- 5Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
- ↵*Corresponding author. Email: mmurtaza{at}tgen.org (M.M.); pockaj.barbara{at}mayo.edu (B.A.P.)
See allHide authors and affiliations
Science Translational Medicine 07 Aug 2019:
Vol. 11, Issue 504, eaax7392
DOI: 10.1126/scitranslmed.aax7392
